Age-related macular degeneration (AMD) is a leading cause of vision loss with approximately 200,000 new diagnoses of its neovascular form each year in the US alone.
Fortunately, many of these patients benefit from antivascular endothelial growth factor (anti-VEGF) pharmaceutical treatments, and such management has changed the epidemiology of blindness in many countries. [2] [3] [4] [5] However, many patients have advanced dry AMD manifest as geographic atrophy or end-stage neovascular AMD associated with macular fibrosis and disciform scarring. The characteristic central scotoma of end-stage AMD, affecting approximately 1.8 million Americans, 6 can significantly limit older adults' ability to perform activities of daily living and engage in social interaction, negatively affecting their quality of life, and increasing rates of depression and dependency on caregivers. 7, 8 In these frustrating clinical situations, where no current pharmaceutical option exists for visual improvement, one may consider refractive visual rehabilitation with implantation of an intraocular telescope.
The Implantable Miniature Telescope (IMT or "telescope implant,"
VisionCare Ophthalmic Technologies, Saratoga, CA) is the only Food and Drug Administration (FDA) approved intraocular telescopic implant for visual rehabilitation in end-stage AMD from geographic atrophy or disciform scarring. The telescope implant is indicated for such bilateral, phakic (in at least one eye) patients with best spectacle-corrected visual acuity (BSCVA) of 20/160-20/800 or worse in both eyes.
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The telescope implant is a fixed-focus, unilaterally implanted device that produces a telephoto effect and enlarges objects in the patient's central visual field by about threefold. Approximately 20-24° of external field of view is projected onto approximately 55° of retina, and therefore, the peripheral field of the implanted eye is reduced. 11 Given the permanent monovision-like situation created with one eye serving central function and the other peripheral function, patient education both before and after surgery is critical to success. To facilitate this, there are more than 120 dedicated CentraSight teams in the US and Europe, which utilize structured steps for patient screening and postimplantation rehabilitation for optimal device utilization and maximization of visual function. 12 Originally approved in 2010, in the fourth quarter of 2014, the FDA expanded the telescope implant label to include patients who are 65 years and older, significantly increasing its potential reach within our aging population.
The device is implanted into the capsular bag by a qualified anterior The most notable reported adverse event was loss of corneal endothelial cell density (ECD). Surgical implantation led to an acute mean ECD loss of approximately 20 %-consistent with that reported following large incision cataract surgery. 13 Subsequently, the reported annual mean ECD loss of 3 % is greater than the reported 0.6 % ECD loss expected annually in healthy eyes but similar to the 2.8 % ECD loss annually reported following large incision conventional cataract surgery and intraocular lens implantation. 14,15 Nevertheless, <3 % of patients reportedly underwent corneal transplantation and surgical explantation was infrequent (5.8 % of implants were removed, primarily due to patient dissatisfaction).
Retinal Imaging and Intravitreal Injecting Following Implantation-Standard Techniques Employed
Following telescope implantation, visualization of the retina is more challenging than through a standard pseudophakic lens. Approximately 0.5 % of eyes may develop active choroidal neovascularization within 2 years of telescope implantation. 13 Optical coherence tomography can be performed through the implant. 16 
Conclusion-Telescope Implant Offers Improved Vision, Sooner
In the 2015 Preferred Practice Pattern Guidelines for AMD, the American Academy of Ophthalmology describes the telescope implant as an option for motivated, end-stage AMD patients. 18 The telescope implant brings hope to a segment of our patients with end-stage AMD, and long-term data indicate that the telescope implant is safe, effective, and capable of improving the visual lives of many patients. ■
